| |
| |
|
| Insider
Information: |
Morrow George J |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
164,177 |
|
|
Indirect Shares
|
5,990 |
|
|
| Direct
Value |
$41,313,741 |
|
|
|
Indirect Value
|
$1,629,959 |
|
|
| Total
Shares |
170,167 |
|
|
| Total
Value |
$42,943,700 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 18.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amgen Inc |
AMGN |
Exe VP, Global Commerc... |
2010-04-29 |
130,488 |
2010-04-29 |
2,717 |
Premium* |
|
|
Align Technology Inc |
ALGN |
|
2024-05-17 |
2,143 |
2024-05-17 |
3,273 |
Premium* |
|
|
Human Genome Sciences Inc |
HGSI |
Director |
2012-07-30 |
0 |
2011-05-12 |
0 |
Premium* |
|
|
Fresh Tracks Therapeutics Ord Shs |
FRTX |
Director |
2015-05-21 |
27,347 |
2012-10-15 |
0 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-05-17 |
4,199 |
2024-03-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
64 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALGN |
Align Technology Inc |
Director |
– • – |
2021-08-02 |
4 |
S |
$705.74 |
$3,536,682 |
I/I |
(5,000) |
12,749 |
0 |
% |
|
| ALGN |
Align Technology Inc |
Director |
– • – |
2015-05-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,500 |
40,900 |
0 |
- |
|
| ALGN |
Align Technology Inc |
Director |
– • – |
2016-05-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,500 |
46,400 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2010-03-12 |
4 |
D |
$57.49 |
$330,740 |
D/D |
(5,753) |
121,290 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2013-05-23 |
4 |
B |
$0.01 |
$60 |
D/D |
5,953 |
12,347 |
2.31 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2012-10-15 |
4 |
B |
$0.01 |
$64 |
D/D |
6,394 |
6,394 |
2.31 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2014-05-22 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
19,847 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2015-05-21 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
27,347 |
0 |
- |
|
| ALGN |
Align Technology Inc |
Director |
– • – |
2013-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,700 |
27,700 |
0 |
- |
|
| ALGN |
Align Technology Inc |
Director |
– • – |
2014-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,700 |
35,400 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2009-05-08 |
4 |
D |
$47.63 |
$418,572 |
D/D |
(8,788) |
113,346 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2011-08-05 |
4 |
B |
$15.79 |
$157,900 |
D/D |
10,000 |
12,500 |
2.39 |
- |
|
| ALGN |
Align Technology Inc |
Director |
– • – |
2023-05-30 |
4 |
GD |
$0.00 |
$0 |
I/I |
10,000 |
3,273 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
• • – |
2012-07-30 |
4 |
D |
$14.25 |
$154,385 |
D/D |
(10,834) |
0 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2008-04-29 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
59,906 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2009-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2010-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
133,290 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2010-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,324 |
127,043 |
0 |
- |
|
| ALGN |
Align Technology Inc |
Director |
– • – |
2021-02-08 |
4 |
S |
$622.19 |
$9,368,969 |
D/D |
(15,000) |
16,478 |
0 |
% |
|
| ALGN |
Align Technology Inc |
Director |
– • – |
2020-10-26 |
4 |
S |
$460.39 |
$8,042,671 |
D/D |
(17,273) |
39,205 |
0 |
% |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2009-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
19,207 |
122,134 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2009-06-09 |
4 |
OE |
$42.13 |
$884,730 |
D/D |
21,000 |
114,719 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2009-06-09 |
4 |
S |
$50.98 |
$1,072,564 |
D/D |
(21,000) |
93,719 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2008-05-12 |
4 |
D |
$41.86 |
$1,125,657 |
D/D |
(26,891) |
93,673 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2007-05-11 |
4 |
D |
$54.25 |
$1,486,504 |
D/D |
(27,401) |
45,297 |
0 |
- |
|
64 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
